false
Andy Kinley
Andy Kinley, Ph.D. is Vice President of Innovation and Clinical Science at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Andy specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Today, Andy identifies and implements innovative tools, datasets, and services that can impact clinical trial execution including quality, patient diversity, site identification, and trial timelines.
-
Read: Clinical Trial Trends: Ovarian Cancer Clinical Trial Trends: Ovarian Cancer
-
Read: Inside a CRO: Operational Strategy and Excellence Discover -
Read: FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma Discover -
Read: Clinical Trial Trends: Radiopharmaceuticals Discover -
Read: Clinical Trial Trends: Acute Myeloid Leukemia (AML) Discover -
Read: Clinical Trial Trends: Breast Cancer Discover -
Read: Clinical Trial Trends: Cell Therapies Discover -
Read: Clinical Trial Trends: Non-small Cell Lung Cancer (NSCLC) Discover -
Read: Driving Oncology Trial Execution with Novel Data-Driven Approaches to Site and Patient Identification Driving Oncology Trial Execution with Novel Data-Driven Approaches to Site and Patient Identification
|
Loading...
You've reach the end